Every 10-Q that Alto Neuroscience Inc. (ANRO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ANRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANRO filings page.
Alto Neuroscience, Inc. reported a larger net loss while significantly strengthening its balance sheet for the quarter ended June 30, 2026. Cash and cash equivalents rose to $243.7 million, up from $176.5 million at year-end 2025, driven mainly by a March 2026 private placement of common stock and pre-funded warrants that generated $114.8 million in net proceeds, plus loan conversions.
Operating expenses increased as the pipeline advanced. For the quarter, research and development expense grew to $22.1 million from $13.1 million, and general and administrative expense to $7.0 million from $5.6 million, producing a loss from operations of $29.1 million. Quarterly net loss was $27.6 million versus $17.7 million a year earlier; six‑month net loss was $53.9 million.
Net cash used in operating activities for the first half of 2026 was $46.9 million. Alto ended the period with total assets of $254.1 million, total liabilities of $34.8 million (including a $15.0 million term loan and a $2.5 million fair‑valued convertible grant), and stockholders’ equity of $219.2 million, supporting ongoing clinical programs such as ALTO‑207, ALTO‑300, ALTO‑100, ALTO‑101, and ALTO‑203.
Alto Neuroscience (ANRO) reported Q3 2025 results highlighted by disciplined spending and solid liquidity to fund its clinical pipeline. Cash and cash equivalents were $137.8 million as of September 30, 2025, with total assets of $147.0 million. Net loss was $14.2 million (vs. $16.8 million a year ago) as research and development and general and administrative expenses declined year over year.
Operating cash outflow was $40.3 million for the nine months, reflecting ongoing clinical execution. During the quarter, Alto amended its term loan to up to $75.0 million, drew $20.0 million, and extended maturity to January 1, 2029 with interest-only payments until January 1, 2027. The Wellcome Convertible Grant Agreement remained in place with $2.1 million measured at fair value as of quarter end.
After quarter close, the company completed a private placement issuing 3,832,263 shares and pre-funded warrants for 4,622,251 shares, for $49.9 million in net proceeds. Shares outstanding were 31,066,335 as of November 7, 2025.
Alto Neuroscience (ANRO) reported unaudited results for the quarter ended June 30, 2025 showing continued clinical progress alongside ongoing operating losses. Cash and cash equivalents were $147.6 million and restricted cash $0.5 million at June 30, 2025, down from $168.2 million at year-end. The company recorded a net loss of $17.7 million for the three months and $32.9 million for the six months ended June 30, 2025, with R&D expense of $23.1 million and G&A of $11.3 million for the six-month period. Accumulated deficit totaled $171.3 million. Financing activity included proceeds from a $20.0 million draw under an amended term loan and an increase in term loan principal and related debt issuance costs; term loan maturity extended to January 1, 2029 with a weighted-average interest rate of 12.96% recorded in 2025. The company has a $2.0 million Convertible Grant Agreement with Wellcome, classified at fair value. Clinical programs advanced: topline data expected mid-2026 for ALTO-300 and in H2 2026 for ALTO-100; acquisition of ALTO-207 and ALTO-208 was completed in May 2025. Management notes continued reliance on external financing to fund operations.